The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells

BACKGROUND: Hypomethylating agents (HMAs), such as decitabine (DAC), are currently used as first-line therapy for patients with high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) not eligible for standard chemotherapies. Exacerbation of thrombocytopenia is one of the prev...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Manag Res
Auteurs principaux: Shi, Mingyue, Xu, Fangfang, Yang, Xiawan, Bai, Yanliang, Niu, Junwei, Drokow, Emmanuel Kwateng, Chen, Mingyi, Chen, Yuqing, Sun, Kai
Format: Artigo
Langue:Inglês
Publié: Dove 2019
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735651/
https://ncbi.nlm.nih.gov/pubmed/31564981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213931
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires